Semaglutide is the licensed once-weekly injectable GLP-1 receptor agonist manufactured by Novo Nordisk and approved for type 2 diabetes (Ozempic) and obesity (Wegovy) indications in the UK, EU, US and internationally. Its rapid clinical adoption across metabolic indications has generated substantial post-marketing safety data and a large real-world clinical-experience base.

Alongside the metabolic-indication licensed use, the compound has attracted growing research interest in brain and cognitive-endpoint applications through multiple angles — direct GLP-1 receptor signalling in CNS tissue, indirect metabolic-improvement-mediated cognitive effects, and the Alzheimer's disease clinical-trial programme represented by the EVOKE Phase III trials.

The FLOW trial was a large multi-year cardiovascular-outcome trial in type 2 diabetes patients with chronic kidney disease that reported cardiovascular and renal endpoint improvements with semaglutide. Cognitive-endpoint sub-analyses provided real-world clinical-context data on the compound's effects in a population at elevated cognitive-decline risk.

The reported cognitive-endpoint sub-analyses were modest but suggestive of neutral-to-positive effects on cognitive measures in the semaglutide arm relative to placebo controls. The sub-analyses are exploratory rather than confirmatory — a Phase III cardiovascular trial's cognitive-endpoint analyses do not replace dedicated cognitive-endpoint trial designs.

The EVOKE programme comprises two Phase III Alzheimer's disease trials, EVOKE (NCT04777396) and EVOKE Plus (NCT04777409), randomising people with early Alzheimer's disease aged 55 and over to once-daily oral semaglutide or oral placebo. The primary outcome registered for each is the change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score from baseline to week 104; 3,808 participants were randomised (1,855 in EVOKE, 1,953 in EVOKE Plus).

ClinicalTrials.gov lists both trials as completed, with a completion date of 30 January 2026. The Lancet report (Cummings et al., 2026, doi 10.1016/S0140-6736(26)00459-9) found that mean change in CDR-SB from baseline to week 104 was 2.3 (EVOKE) and 2.2 (EVOKE Plus) with semaglutide against 2.3 and 2.1 with placebo; the authors concluded that oral semaglutide was not efficacious in slowing clinical progression in early Alzheimer's disease and report both trials as discontinued for negative clinical outcome.

The preclinical GLP-1 CNS research evidence base characterises GLP-1 receptor signalling on CNS neuronal populations relevant to cognitive function, with effects including neuroprotection in ischaemic and neurodegenerative disease models, anti-inflammatory effects on microglial populations, and modulation of hippocampal long-term potentiation.

The mechanistic characterisation provides a plausible scaffold for the cognitive-relevance research applications, though direct extrapolation to clinical cognitive-endpoint effects is not supported by the EVOKE Phase III results (Lancet, 2026), which showed no slowing of clinical progression in early Alzheimer's disease.

The semaglutide brain and cognitive-endpoint research evidence base is currently mixed — with substantial preclinical CNS characterisation, exploratory Phase III sub-analyses, and the EVOKE Phase III trials, whose primary endpoint showed no slowing of clinical progression (Lancet, 2026). Cognitive-endpoint claims about semaglutide in early Alzheimer's disease are therefore not supported by the confirmatory trials.

For clinical purposes semaglutide is licensed for metabolic indications only; cognitive indications are not among the indications in the Ozempic or Wegovy SmPC.